Russell SJ, et al. – This phase 2, double-blind, randomized, parallel-group trial of 33 patients with knee osteoarthritis and comorbid type 2 diabetes mellitus (T2DM) compared blood glucose levels after intra-articular injection of triamcinolone acetonide extended-release (TA-ER)—an extended-release, microsphere-based triamcinolone acetonide formulation—vs standard triamcinolone acetonide crystalline suspension. Between groups, non-glycemic adverse events were mild in severity and comparable. In patients with knee osteoarthritis and T2DM, findings showed that TA-ER may enable intra-articular corticosteroid treatment with minimal blood glucose disruption.